Eliquis
Product Images NDC 67296-1673

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Eliquis (NDC 67296-1673). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Redpharm Drug, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

67296 1673 7

This is a description of a medication called ELIQUIS (APIXABAN) 5MG, containing 14 tablets, with a lot number of 774738X1 and an expiration date of 05/23. The recommended adult dosage is contained in the package insert. The manufacturer is Bristol-Myers Squibb Company located in Princeton, NJ, and the product is distributed by Redpharm Drug in Eden Prairie, MN. The medication should be stored at a controlled room temperature of 20-25 C (68-77 F).*

FDA Label Image

Label (Eliquis 1673)

The text contains information about Eliquis (Apixaban) tablets, including the NDC, dosage, lot number, and expiration date. It also provides instructions to store the medication at room temperature and to refer to the package insert for the recommended adult dosage. The manufacturer, Bristol-Myers Squibb Company, and distributor, Redpharm Drug, are listed along with their locations. The second section of text appears to contain similar information for a larger quantity of tablets in a different lot, also with a recommendation to store at room temperature and to refer to the package insert for the usual adult dosage.*

FDA Label Image

Apixaban Chemical Structure (Apixaban Struct)

FDA Label Image

Aristotle Forest Plot (Eliquis Clin Forest Fig5)

FDA Label Image

Aristotle Major Bleeding Forest Plot (Eliquis Forest Fig1)

This appears to be a table with information related to various subgroups of patients in a study comparing Apixaban and Warfarin for treating a medical condition. The information includes the number of events and number of patients per year and hazard ratio between the two medications. Additionally, there is information on subgroups based on various criteria such as age, weight, stroke or TIA history, diabetes, creatinine clearance, geographic region, and whether randomized or not. However, the exact medical condition, purpose of the study, and other relevant details are not mentioned.*

FDA Label Image

Aristotle Kaplan-meier Curve (Eliquis Km Fig4)

Not available.*

FDA Label Image

Effect Of Coadministered Drugs On Pharmacokinetics Of Apixaban (Eliquis Pkplot Drugs Fig2)

This is a table showing the fold change and 90% confidence interval of interacting drugs with P-gp and strong CYP3A4 inhibitors, other CYP3A4 and P-gp inhibitors, and P-gp and strong CYP3A4 inducers. The drugs include Ketoconazole, Glarithromycin, Diltiazem, Naproxen, and Rifampin. The table provides information on the AUC (area under the curve) for each drug at different doses. It also shows the change relative to the reference drug.*

FDA Label Image

O:\e-submissions\pbo\products\eliquis 202155\08. Pas Esrd Dosing\01. Orig Submission\source\eliquis-pkplot-pop-fig3.jpg (Eliquis Pkplot Pop Fig3)

This is a medication dosing guide that provides recommendations on dose adjustments based on various population descriptions such as renal or hepatic impairment, age and body weight. It includes fold changes and 90% confidence intervals for PK. The guide suggests if no dose adjustment is needed or if a dosing recommendation can't be provided.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.